GBT Pharma has acquired Swiss OTC brand Phytovir®, for an undisclosed sum.
Specialists in international market access for OTC companies and brands, GBT Pharma have represented Phytovir, a range of products to care for cold sores caused by the herpes simplex virus (HSV1) since 2011.
In that time GBT devised a market entry programme driving incremental growth for Phytovir across major markets such as Latin America and Europe. Launched initially into Swiss pharmacies in 2003, the range, including a topical cream, patches, a lip salve with sun protection and later, a food supplement line, became known for its antiviral and wound healing properties.
Backed by clinical and open-label studies, the range has demonstrated clinical efficiency equivalent to that of the market leading brand, along with a good safety profile and lesser likelihood of creating viral resistance.
Dr Gian Trepp, CEO of GBT Pharma comments: “We are proud to have supported this fantastic Swiss brand as it becomes more well-known across the world and are delighted to have secured the rights for Phytovir. We have big plans for the brand and look forward to welcoming enquiries from possible distribution partners not only in LATAM, but across Europe too.”
Geni Merz from Phytovir AG added: “With their established network and combined industry knowledge, Phytovir could not be in better hands as it enters its next phase with GBT Pharma. Over the last seven years they have consistently demonstrated their passion for the brand and there is no team better equipped to take Phytovir forward in the international OTC sector.”
Companies interested in details on distribution opportunities are invited to get in touch.